Article
Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2003
Nakanishi Takeo, Karp Judith E, Tan Ming, Doyle L Austin, Peters Todd, Yang Weidong, Wei David, Ross Douglas D
Abstract excerpt
PURPOSE: Flavopiridol is a cyclin-dependent kinase inhibitor currently undergoing human clinical trials. As clinical development is pursued, it becomes important to evaluate resistance mechanisms to flavopiridol. To elucidate the contribution of breast cancer resistance protein (BCRP) to cellular resistance to flavopiridol in acute myeloid leukemia, we studied the relationship between cellular resistance to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.